Achieve Life Sciences (ACHV) Cash & Equivalents (2010 - 2026)

Achieve Life Sciences has disclosed Cash & Equivalents across 17 years of filings, most recently posting $29.3 million for Q1 2026.

• Quarterly Cash & Equivalents rose 26.29% year-over-year to $29.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.3 million (up 26.29% YoY) and the FY2025 annual result came in at $20.9 million, up 64.11% from the prior year.
• Cash & Equivalents rose to $29.3 million in Q1 2026, from $20.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $66.4 million in Q1 2024 and troughed at $12.8 million in Q4 2024.
• A 5-year average of $31.4 million and a median of $25.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 420.4% — and 2025, when it slumped 65.06%.
• Tracing ACHV's Cash & Equivalents over 5 years: stood at $22.8 million in 2022, then tumbled by 37.37% to $14.3 million in 2023, then fell by 10.52% to $12.8 million in 2024, then jumped by 64.11% to $20.9 million in 2025, then surged by 40.0% to $29.3 million in 2026.
• Business Quant data shows ACHV's Cash & Equivalents at $29.3 million in Q1 2026, $20.9 million in Q4 2025, and $48.1 million in Q3 2025.